UAMS venture gets $14.5 million to study drug to combat meth addiction | Arkansas Blog

Thursday, January 29, 2015

UAMS venture gets $14.5 million to study drug to combat meth addiction

Posted By on Thu, Jan 29, 2015 at 11:30 AM

BioVentures, the biotechnical arm of the University of Arkansas for Medical Sciences, announced today that one of its startups, InterveXion Therapeutics, has received two NIH grants worth $14.5 million to develop a drug to combat methamphetamine addiction. The money will help the company, founded in 2004, work on a vaccine for clinical trials; the other will support production of a meth antibody already tested in a clinical study of healthy adults.

BioVentures is one of the lynchpins of the development of the Little Rock Technology Park. Could the production of the antibody be something that would move into the park? I've asked. UPDATE:  Mike Owens, who developed both the vaccine and the antibody, says no. 

Here's the press release from UAMS: 

InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users

LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.

The therapies are designed to reduce or prevent the euphoric rush that drug users crave by keeping methamphetamine in the bloodstream and out of the brain, where the drug exerts its most powerful effects.

The larger of the two grants, $9.55 million over three years, will support research that will determine whether a methamphetamine vaccine may be safely advanced into a clinical trial with human participants. The vaccine is a promising new strategy that could stimulate a patient’s own immune system to generate long-acting, protective anti methamphetamine antibodies.

The other grant of $5 million over three years will support production of the anti-methamphetamine monoclonal antibody that has been successfully tested in a first clinical study of healthy adults. The grant will also fund more research to show that the antibody is safe for methamphetamine users. The additional study will prepare researchers for the next clinical trial involving methamphetamine-using participants.

This antibody does not stimulate the immune system, but it selectively and quickly binds methamphetamine in the blood and prevents it from entering the brain and other tissues where it causes multiple health problems, including addiction. It would be the first medication that can reduce methamphetamine’s effects for prolonged periods of time.

The antibody has an immediate impact on the user and is effective for about a month. The vaccine takes several weeks to become effective, and it may blunt methamphetamine’s effects for nine months or longer.

Both grants are to InterveXion from the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA). UAMS is a sub-awardee.

“These grants represent NIDA’s commitment to addressing methamphetamine abuse with promising therapies such as the monoclonal antibody and vaccine,” said UAMS’ Mike Owens, Ph.D., who developed both the vaccine and the antibody and has received NIDA funding since the mid-1980s.

“Our team demonstrated the safety of the monoclonal antibody in a clinical trial completed last year, and we look forward to the next phases of research with both the antibody and the vaccine,” he said.

Owens is co-program director and co-principal investigator on the vaccine grant. He is a professor and director of the UAMS Center for Alcohol and Drug Abuse and InterveXion’s chief science officer.

W. Brooks Gentry, M.D., is co-program director and co-principal investigator on the monoclonal antibody grant. He is a professor and chair of the Department of Anesthesiology in the UAMS College of Medicine and InterveXion’s chief medical officer.

Misty Stevens, Ph.D., M.B.A., is operations director for InterveXion and is co-program director and co-principal investigator for both grants. Ralph Henry, Ph.D., is vice president for biopharmaceutics at InterveXion and a co-investigator on both grants.

Assuming the antibody and vaccine receive federal Food and Drug Administration (FDA) approval, they can be provided as an integral part of a methamphetamine user’s complete treatment program, which consists of counseling and possibly other medications to reduce craving.

“The two drug therapies may also be used together,” Stevens said. “The antibody could provide a patient with immediate protection while the patient is building immunity following administration of the vaccine.”

Neither the monoclonal antibody nor the vaccine should interact with other medications, nor should they impact brain function or interfere with psychiatric counseling. The vaccine would be less expensive than the antibody, but it is expected to be less effective for some people, especially those with compromised immune systems.

InterveXion is a pharmaceutical company whose mission is to discover and advance innovative medications that reduce the impact of human suffering on individuals and communities. Its vision is to be a leader in the development of antagonist therapies that neutralize toxins in the body and thereby improve patient health. InterveXion’s first medications are a monoclonal antibody and an active vaccine for treating methamphetamine abuse. For more information, contact

Tags: ,

Sign up for the Daily Update email

Comments (2)

Showing 1-2 of 2

Add a comment

Subscribe to this thread:
Showing 1-2 of 2

Add a comment

More by Max Brantley

  • Where's the outrage?

    Am I the only person, apart from federal prosecutors, outraged about the criminal enterprise that inveigled itself into a privileged position as an Arkansas taxpayer-financed human services provider to the tune, today, of $43 million a year?
    • Jun 21, 2018
  • Where's the outrage?

    • Jun 21, 2018
  • Rutledge opponent hits her socializing with corporate interests

    Mike Lee, the Democratic candidate for attorney general, has criticized Attorney General Leslie Rutledge over recent reports of her participation at private meetings where corporate interests make big contributions to a political group she heads for access to state legal officers.
    • Jun 21, 2018
  • More »

Readers also liked…

Most Viewed

Most Recent Comments



© 2018 Arkansas Times | 201 East Markham, Suite 200, Little Rock, AR 72201
Powered by Foundation